



MGB Alert® N2-B Primers

This package insert applies to REF 800346



Nanogen, Inc.
10398 Pacific Center Court
San Diego, CA 92121 USA | Phone: 1.858.410.4600 | Fax: 1.858.410.4952

Product Description

MGB Alert® N2-B Primers contains chemically synthesized DNA oligonucleotides designed to amplify the MGB Alert® Internal Control 2. The mix consists of two primers at a total of 9.92 nmol per vial in a 1X TE buffer solution. The primers amplify the following target DNA fragment of the MGB Alert® Internal Control 2:

5'-CTGCACGGACCAGTTACTTTACGGACCACGTACCGCATTGGTACAAGATCTCCGGTAGAAAAAATGAG-3'

Storage and Storage Stability

The reagent contained in this package should be protected from light and stored at $\leq -20^{\circ}\text{C}$. The reagent must be used by the expiration date printed on the vial label. Product use is limited to five freeze-thaw cycles.

Technical Assistance Center

For Technical Assistance, please call toll free 1.877.NANOGEN (1.877.626.6436) or
email: technicalassistance@nanogen.com

Limited Product Warranty

Nanogen, Inc. warrants that this product will meet the specifications stated above. If any component of this product does not conform to these specifications, Nanogen, Inc. will at its sole discretion, as its sole and exclusive liability and as the users' sole and exclusive remedy, replace the product at no charge or refund the cost of the product; provided that notice of non-conformance is given to Nanogen, Inc., within sixty (60) days of receipt of the product.

This warranty limits Nanogen, Inc.'s liability to the replacement of this product or refund of the cost of the product. NO OTHER WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT, ARE PROVIDED BY NANOGEN, INC. Nanogen, Inc. shall have no liability for any direct, indirect, consequential or incidental damages arising out of the use, the results of use or the inability to use this product and its components.

In no event shall Nanogen be liable for claims for any other damages, whether direct, incidental, foreseeable, consequential, or special (including but not limited to loss of use, revenue or profit), whether based upon warranty, contract, tort (including negligence) or strict liability arising in connection with the sale or use or the failure of Nanogen products to perform in accordance with the stated specifications.

Some components of nucleic acid analysis, such as specific methods and compositions for manipulating or visualizing nucleic acids for analysis, may be covered by one or more patents owned by other parties. Similarly, nucleic acids containing specific nucleotide sequences may be patented. Making, using, offering for sale, or selling such components or nucleic acids may require one or more licenses. Nothing in this document should be construed as an authorization or implicit license to make, use or sell any so covered component or nucleic acid under any such patents.

Licensing and legal notice

MGB Alert® detection reagents are covered by one or more of U.S. Patents Nos. 5,801,155, 6,127,121, 6,312,894, 6,426,408, 6,485,906, 6,492,346, 6,660,845, 6,727,356, 7,319,022 and RE 38,416 as well as applications that are currently pending.

Purchase of this product carries with it a limited, non-transferable, non-exclusive license (without the right to resell, repackage, or sublicense) under U.S. Patent Nos. 6,030,787, 5,723,591, and 5,876,930, and corresponding foreign patents, to use the product solely in an ASR in which the detection of a nucleic acid sequence does not include the cleavage of a nucleic acid probe, and for no other purpose. No other license under these patents or any other patents is granted expressly, by implication or by estoppel. This limited license permits the person or legal entity to which this product has been provided to use the product, and the data generated by use of the product, only: (a) for internal ASR assay validation purposes involving hybridization-based analysis of nucleic acids; and (b) for clinical diagnostics as an Analyte Specific Reagent, as that term is defined and restricted by the U.S. Food and Drug Administration in 21 CFR 864.4020 and 21 CFR 809.30. Neither Nanogen, Inc. nor any of its licensors grants any other licenses, whether express or implied, for any other purposes. No license under the PCR process is conveyed through purchase of this product. Further information on purchasing licenses to practice the PCR process may be obtained by contacting the Director of Licensing at Applied Biosystems, 850 Lincoln Centre Drive, Foster City, California 94404 or the Licensing Department, Roche Diagnostics, Grenzacherstrasse 124, CH-4070, Basel, Switzerland.

Trademarks:

Nanogen® is a registered trademark of Nanogen, Inc.
MGB Alert® is a registered trademark of Nanogen, Inc.